Alpha Cognition Secures New Patent for Zunveyl
Alpha Cognition announced that the United States Patent and Trademark Office has issued a new patent entitled "Dosage Regimens for Benzgalantamine." The patent covers methods of orally administering benzgalantamine for the treatment of mild to moderate Alzheimer's disease using specific dosing regimens. "This newly issued patent meaningfully strengthens the intellectual property protection surrounding Zunveyl by covering clinically relevant dosing regimens for oral administration," said Michael McFadden, CEO of Alpha Cognition.
